menu
    • menu
    [{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nutcracker Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Nutcracker Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NTX-470","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nutcracker Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutcracker Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Nutcracker Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Nutcracker Therapeutics

    Menu

    Nutcracker Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nutcracker Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            Nutcracker Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTX-470

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nutcracker Therapeutics to Present mRNA Drug Data at AACR 2024

                            Details : NTX-470, a novel multispecific T cell engager expressed from mRNA targets PSMA and STEAP1 prostate cancer antigens to generate enhanced functional activity. It is being evaluated for prostate cancer.

                            Product Name : NTX-470

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            December 03, 2024

                            Lead Product(s) : NTX-470

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nutcracker Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed

                            Nutcracker Therapeutics

                            U.S.A arrow
                            APS Symposium
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Arch Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Nutcracker Therapeutics Radies $60M Series B Financing for an mRNA Therapeutics Produced on Transformational B...

                            Details : Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Arch Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth